Nathan Rice
Stock Analyst at Piper Sandler
(3.64)
# 684
Out of 4,820 analysts
52
Total ratings
45.45%
Success rate
8.56%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFC Bank First | Maintains: Neutral | $110 → $111 | $110.15 | +0.77% | 6 | Apr 17, 2025 | |
| MBIN Merchants Bancorp | Maintains: Overweight | $53 → $57 | $32.43 | +74.25% | 7 | Jan 30, 2025 | |
| FMBH First Mid Bancshares | Maintains: Overweight | $46 → $47 | $33.26 | +41.31% | 3 | Nov 1, 2024 | |
| BY Byline Bancorp | Reiterates: Overweight | $34 | $25.61 | +32.76% | 8 | Oct 29, 2024 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $65.32 | +13.29% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $115.81 | -27.47% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $183.35 | +7.44% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $9.44 | -4.66% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $437.50 | -0.57% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $335.36 | -30.52% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $57.69 | +43.87% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $15.49 | -3.13% | 1 | Dec 19, 2019 |
Bank First
Apr 17, 2025
Maintains: Neutral
Price Target: $110 → $111
Current: $110.15
Upside: +0.77%
Merchants Bancorp
Jan 30, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $32.43
Upside: +74.25%
First Mid Bancshares
Nov 1, 2024
Maintains: Overweight
Price Target: $46 → $47
Current: $33.26
Upside: +41.31%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $25.61
Upside: +32.76%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $65.32
Upside: +13.29%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $115.81
Upside: -27.47%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $183.35
Upside: +7.44%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $9.44
Upside: -4.66%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $437.50
Upside: -0.57%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $335.36
Upside: -30.52%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $57.69
Upside: +43.87%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $15.49
Upside: -3.13%